{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:41:57Z","timestamp":1772160117651,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010215","name":"Deutsche Diabetes Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of initiating basal insulin\u2010supported oral therapy (BOT) with insulin glargine 300\u2009U\/mL (Gla\u2010300) in patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs (OADs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This non\u2010interventional, multi\u2010centre, prospective 52\u2010week study, conducted in Germany and Switzerland, documented patients with type 2 diabetes with an HbA1c of between 7.5% and 10.0%, currently treated with OADs, after the physician had decided to start a BOT regimen with Gla\u2010300. The primary endpoint was the rate of achievement of the individualized predefined HbA1c target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1748 patients included, 1153 comprised the full analysis set, of whom 721 completed documentation of 12\u2009months of Gla\u2010300 treatment. Twelve months after starting Gla\u2010300, 49.9% achieved their individualized HbA1c target, and 61.1% achieved either their HbA1c target or a fasting plasma glucose (FPG) of \u2264110\u2009mg\/dL. Mean HbA1c decreased by \u22121.22%\u2009\u00b1\u20091.05% to 7.28%\u2009\u00b1\u20090.92% and mean FPG by \u221251.5 (\u00b148.63) mg\/dl to 132.9\u2009\u00b1\u200933.0\u2009mg\/dL. Median duration of HbA1c target achievement was 341\u2009days and probability to remain on target after 6\u2009months was 81%. Hypoglycaemia incidence and rates remained low after 12\u2009months of Gla\u2010300 treatment; no severe or severe nocturnal hypoglycaemia was observed. Body weight remained unchanged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Starting a BOT regimen with Gla\u2010300 allowed about 60% of 721 German and Swiss patients with inadequately controlled type 2 diabetes to achieve glycaemic control within 12\u2009months in daily clinical practice. Glycaemic control was achieved without weight gain or increased risk of nocturnal or severe hypoglycaemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13952","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T23:55:42Z","timestamp":1578268542000},"page":"759-766","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effectiveness and safety of insulin glargine 300\u2009U\/mL in insulin\u2010na\u00efve patients with type 2 diabetes after failure of oral therapy in a real\u2010world setting"],"prefix":"10.1111","volume":"22","author":[{"given":"Martin","family":"Pfohl","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Evang. Bethesda\u2010Hospital Duisburg  Duisburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois R.","family":"Jornayvaz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology, Hypertension and Nutrition University Hospital of Geneva  Geneva Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Fritsche","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV University of Tuebingen  Tuebingen Germany"},{"name":"Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tuebingen (IDM)  Tuebingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Pscherer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III Sophien\u2010 and Hufeland\u2010Hospital  Weimar Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Anderten","sequence":"additional","affiliation":[{"name":"Joint Practice Anderten\u2010Krok &amp; Partner  Hildesheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Pegelow","sequence":"additional","affiliation":[{"name":"Sanofi\u2010Aventis Deutschland GmbH  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-7310","authenticated-orcid":false,"given":"Jochen","family":"Seufert","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center \u2013 University of Freiburg Faculty of Medicine, University of Freiburg  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012527"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.9-a.s5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2014.970633"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.04.007"},{"key":"e_1_2_9_8_1","unstructured":"Bundes\u00e4rztekammer (B\u00c4K) Kassen\u00e4rztliche Bundesvereinigung (KBV) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ\u20102\u2010Diabetes \u2013 Langfassung 1. Auflage. Version 3.2013 zuletzt ge\u00e4ndert: April 2014.http:\/\/www.versorgungsleitlinien.de\/themen\/diabetes2\/dm2_therapie; [cited: November 14 2019];https:\/\/doi.org\/10.6101\/AZQ\/000203. Accessed November 14 2019."},{"key":"e_1_2_9_9_1","unstructured":"LehmannR BiandaT Br\u00e4ndleM et al. Empfehlungen der SGED\/SSED: Massnahmen zur Blutzuckerkontrolle bei Patienten mit Diabetes mellitus Typ 2. Empfehlungen der SGED 24. August2016 rev. 30. M\u00e4rz 2017.https:\/\/www.sgedssed.ch\/fileadmin\/user_upload\/6_Diabetologie\/61_Empfehlungen_Facharzt\/1703_SGED_Empfehlung_BZ\u2010Kontrolle_T2DM_Finale_Version_13_oTabellen.pdf. Accessed November 14 2019."},{"key":"e_1_2_9_10_1","volume-title":"Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice","author":"Bradley C","year":"1994"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0559"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13793"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13693"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13535"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","unstructured":"PschererS AndertenH PfohlM et al. Titration of insulin glargine 100 U\/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP\u20101 real\u2010world study [published online ahead of print July 24 2019].Acta Diabetol.https:\/\/doi.org\/10.1007\/s00592-019-01383-w.","DOI":"10.1007\/s00592-019-01383-w"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000409"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.01.030"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejsp.401"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13952","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13952","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13952","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:41:28Z","timestamp":1761892888000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1111\/dom.13952"],"URL":"https:\/\/doi.org\/10.1111\/dom.13952","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.13952\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v2\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13952\/v2\/review2","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"assertion":[{"value":"2019-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}